Targeting Ferroptosis to Enhance the Efficacy of BRAF/MEK Inhibitors in Overcoming Resistance in Melanoma (EACR 2025) - Jun 29, 2025 - Abstract #P-312; Pres time: Jul 17, 2025; 10:45 AM - 08:00 PM; Location: Poster and Exhibition Hall; Poster Board No EACR25-1612; "Ferroptosis induction was assessed using specific inhibitors and activators of this pathway, such as RSL3 and erastin. Cell viability assays, gene expression analysis, and western blotting were performed to measure the effects of ferroptosis induction alone and in combination with BRAF/MEK inhibitors (e.g., vemurafenib and trametinib)... The induction of ferroptosis presents a promising strategy for enhancing the efficacy of BRAF/MEK inhibitors in the treatment of melanoma. Our findings suggest that ferroptosis could overcome treatment resistance and improve therapeutic outcomes in patients with advanced melanoma. Further preclinical and clinical studies are warranted to validate these results and optimize combination strategies involving ferroptosis and targeted inhibitors."
Clinical • Melanoma • Oncology • Solid Tumor
|
|
M. Quindos-Varela 1; R. Lesta-Mellid 1; I. Santamarina-Cainzos 1; S. Rodríguez-Varela 1; I. Martínez-Martín 1; M. Fraga 1; M. Quintela 2; M. Arufe 3; J. Fafian-Labora 3
|